Advertisement
UK markets closed
  • FTSE 100

    8,174.53
    +53.33 (+0.66%)
     
  • FTSE 250

    20,459.19
    +264.72 (+1.31%)
     
  • AIM

    769.79
    +5.42 (+0.71%)
     
  • GBP/EUR

    1.1815
    +0.0015 (+0.13%)
     
  • GBP/USD

    1.2763
    +0.0078 (+0.62%)
     
  • Bitcoin GBP

    47,161.75
    -1,380.59 (-2.84%)
     
  • CMC Crypto 200

    1,298.59
    -36.33 (-2.72%)
     
  • S&P 500

    5,521.19
    +12.18 (+0.22%)
     
  • DOW

    39,273.01
    -58.84 (-0.15%)
     
  • CRUDE OIL

    82.70
    -0.11 (-0.13%)
     
  • GOLD FUTURES

    2,371.60
    +38.20 (+1.64%)
     
  • NIKKEI 225

    40,580.76
    +506.07 (+1.26%)
     
  • HANG SENG

    17,978.57
    +209.43 (+1.18%)
     
  • DAX

    18,387.82
    +223.76 (+1.23%)
     
  • CAC 40

    7,644.36
    +106.07 (+1.41%)
     

Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant

Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant
Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant

French drugmaker Sanofi is poised to commit between 1.3 billion euros and 1.5 billion euros ($1.4 billion – $1.6 billion) to enhancing its insulin production site in Frankfurt, Germany.

The site in Frankfurt’s Hoechst district is known for producing the company’s insulin brand, Lantus.

Also Read: Hawaii Court Rules Against Bristol Myers, Sanofi In Blood Clot Drug Case, Increases Liability To $916M.

This move comes after initial plans to shift Lantus production to France were reconsidered.

The decision to invest in the Frankfurt site represents a significant victory for Germany’s healthcare sector.

Germany’s ruling coalition has been actively working to attract healthcare investments. In February, Daiichi Sankyo announced plans to spend around 1 billion euros to advance its precision cancer drug work near Munich.

ADVERTISEMENT

Eli Lilly (NYSE:LLY) also committed 2.3 billion euros last November to produce obesity and diabetes medications in Germany.

Sanofi’s investment is expected to bolster its production capabilities and reinforce its commitment to maintaining a strong manufacturing presence in Germany.

Reuters noted that the upgrade will likely enhance Lantus’s supply chain stability and support Sanofi’s long-term strategic goals.

In May, Sanofi announced an investment of more than €1 billion to create new bioproduction capacity at its French sites in Vitry-sur-Seine (Val de Marne), Le Trait (Seine-Maritime), and Lyon Gerland (Rhône).

Read Next:

Price Action: At the last check on Monday, SNY shares were up 1.96% at $49.47.

Image by HJBC via Shutterstock

"ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock Market Game with the #1 "news & everything else" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!

Get the latest stock analysis from Benzinga?

This article Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant originally appeared on Benzinga.com

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.